BD Diagnostics announced that it has received FDA approval to market BD MAX MRSA molecular test, a new test that is designed to rapidly and accurately identify patients colonized with methicillin-resistant Staphylococcus aureus (MRSA).
MRSA is a superbug that causes infections primarily in people who have been in hospitals or other healthcare settings. The BD MAX System is a fully automated sample-to-result platform that rapidly identifies colonized patients, enables prompt implementation of contact precautions and infection control measures, and improves patient outcomes and reduces the risk of transmission.
The BD MAX MRSA assay is the second test cleared this year by the FDA on the BD MAX System.
For more information call (888) 232-2737 or visit www.bd.com.